Nifty Pharma Trades In Red

Nifty Pharma was trading in the negative territory during Wednesday’s trading session along with the foremost benchmark indices. Nifty Pharma was trading down through 0.98% at 8,920.75 levels on NSE at 1001 hours.

Nifty Pharma used to be trading within the bad territory throughout Wednesday’s trading session together with the foremost benchmark indices. Nifty Pharma was trading down through 0.98% at 8,920.75 levels on NSE at 1001 hours.

Sun Pharma used to be the top loser in the index, trading decrease by 2.31% at Rs 480 per shares. The stock attracted total traded volume of 21,11,536 shares and traded price of Rs 10,155.22 lakh on NSE at 1003 hours.

Divis Laboratories was trading lower by using just about 2% at Rs 710 per shares and Lupin used to be trading lower by 1.26% at Rs 980 per share.

Among others, Dr. Reddy was trading down through 0.81% at Rs 2,191 per share, Cadila Healthcare was once trading lower by means of 0.seventy three% at Rs 506 per share, Glaxo was once trading down through zero.sixty two% at Rs 2,439 per share, PEL used to be dipped by using 0.17% at Rs 2,693 per share and Aurobindo Pharma used to be trading down by means of 0.13% at Rs 743 per share.

Glenmark Pharma used to be trading flat all the way through Wednesday’s trading session. The stock was once just about hit its 52-week low at Rs 591.75 per share.

Meanwhile, the major benchmark indices Sensex used to be trading lower by way of 180 points at 21,629 levels and Nifty 50 trading down by 52.20 points at 9,900 levels.

Wealth It Global provides you Trading tip calls about the Indian stock markets with intense analysis done by our Team of Analysts. We have been providing valuable Tips to our clients through various methods. We have helped lot of retail and HNI client through our tips services to fulfill their financial goals by making their money work for them a better way. We try to follow the trend and ride it using technical analysis rather than predicting customer's needs.

Contact Us- 9798199199


Comments

Popular posts from this blog

Positive Opening Likely Following Robust Overall Cues

Markets May Remain Risky Because of September Collection F&O Expiry

Market appears absolutely valued, continue to predict consolidation in close to term: JPMorgan